GMAB

Genmab A/SB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$44.00

+84.5% vs current

Most likely

Base case

45%

Probability

Target price

$36.86

+54.5% vs current

B-

Bear case

30%

Probability

Target price

$21.00

-11.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-28

AI commentary

Primary-source evidence points to a credible but cautious monitor: Q1 showed strong royalty-led growth and guidance was maintained, yet forward visibility still hinges on a few oncology readouts and launch preparations. Analyst revision data are unavailable in the packet, and the post-earnings market response appears mixed in secondary coverage, so confidence stays moderate-to-low rather than bullish.

RankAlpha Sentiment Codex - 2026-05-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07eventQ1 2026 results kept royalty growth and guidance intactMedium impact

Genmab reported Q1 revenue of $896M, up 25% year over year, driven mainly by higher DARZALEX and Kesimpta royalties plus higher EPKINLY sales; operating expenses rose as the company kept investing in Rina-S and petosemtamab, and management maintained 2026 guidance. [#10Q-GMAB-2026Q1]

2026-05-29eventASCO/EHA 2026 oncology data slate keeps epcoritamab in focusMedium impact

Genmab said 23 abstracts will be presented or published at ASCO and EHA 2026, including 20 abstracts evaluating epcoritamab, so the near-term readthrough is concentrated on the blood-cancer franchise rather than a broad pipeline reset. [#IR-GMAB-ASCO2026]

2026-10-31catalystRina-S and petosemtamab remain the main longer-dated rerating pathMedium impact

Genmab is still funding launch readiness for Rina-S and petosemtamab, and official Genmab releases show Rina-S ovarian-cancer safety/tolerability updates plus an earlier FDA breakthrough designation in endometrial cancer, keeping these programs central to the longer-term rerating case. [#PR-GMAB-RinaS-2026-04-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-28 • Updated nightlySource: Internal modelMethodology